Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Jagat Kanwar is an Associate Professor of Immunology & Cell Biology, and Group Leader in “Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research” at Deakin University, Australia. He did his PhD in 1993 from PGIMER, Chandigarh, India and worked as a Senior Scientist in The Auckland University, New Zealand for more than 10 years. He has a national and international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. His research is also focused on miRNA, aptamer, locked nucleic acid (LNA) LNA-modified chimeric aptamers-siRNA conjugates, and immunoliposomes technology and disease targeted drug discovery. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. He designed nanocarriers for applications in vaccines, immunotherapy, and drug delivery of antigens immunostimulatory ligands to dendritic cells and subsequent stimuli to T- lymphocytes, B-lymphocytes and TH17 cells.
Cancer and chronic inflammatory diseases targeted nanomedicine based drug delivery siRNA, miRNA anti-sense targeted gene nanomedicine based technology to target cancer and inflammation.
Drug discovery with anticancer targets for cancer cell survival, death, arrest and repair. Development of recombinant proteins and searching new immunomodulatory and anti-inflammatory bioactives, proteins and peptides for cancer and neuroprotection.
Development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of colon and breast cancers.
Development of oral and intravenous administration of nanocarriers to overcome the challenging concept of drug resistance in various cancers.
Development of new generation safe, biodegradable, less toxic, disease targeted natural contrast materials for imaging.
Novel nano-medicinal based vaccines and immunotherapy Micro-fluidics and Lab-on-a-Chip devices for delivery and diagnosis.
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals